“The gel, Sina amfulish, has been developed by researchers at Eksir Nano Sina knowledge-based company to treat leishmaniasis,” said Mahanz Qomi.
Stating that Sina amfulish is a topical drug, she asserted that, “leishmaniasis is the most common skin disease which is transmitted to humans by the bite of a specific kind of fly marking lack of sanitation and poverty as the main causes of this disease.”
“This parasite remains in the body and had no definite cure; however, our company could make the drug treatment for leishmaniasis which obtained a patent,” she added.
He stated that 12 million people worldwide are infected with leishmaniasis asserting that in Iran, 30 thousand people are suffering from this disease and this number is growing every year.
“Indeed, there exist some drugs which are injected into the skin wound directly to kill the leishmaniasis parasite but this parasite has become resistant to those drugs and meanwhile the injection is painful and has side effects,” noted Qomi.
Announcing that Sina amfulish can treat leishmaniasis in three weeks, she said that, “this drug has successfully passed the animal test phase and is at the human phase now while its third phase of clinical trial is being carried out in a leprosy center under the supervision of the Ministry of Health.”
Emphasizing that more than 95% of patients under experience were treated in three weeks, the researcher added that, “we have had correspondence with the World Health Organization (WHO) and they have been informed about the production of this drug by an Iranian knowledge-based company; we are expecting a good global market for this drug but it must first be presented to the Iranians.”
She also said that a Syrian delegation will come to Iran in October to buy the drug noting that, “however, apart from Syria, Iraq, Brazil, South Africa could also be candidates for this drug.”
HA/2913309
Your Comment